Le Lézard
Classified in: Health, Science and technology, Business
Subjects: NEW PRODUCTS/SERVICES, STOCK/OTHER MARKET NEWS

Bright Minds Biosciences Comments on Recent Trading Activity


VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is issuing this news release in response to a request by the Investment Industry Regulatory Organization of Canada ("IIROC") to comment on recent trading activity of its stock.

The Company is not aware of any material, undisclosed corporate developments and has no material change in its business or affairs that has not been publicly disclosed that would account for the recent increase in volume or price. In accordance with applicable disclosure requirements, the Company will advise the market of material changes, if any when they occur.

About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds' drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Investor Contacts:
Ian McDonald
CEO and Director
E: [email protected]
T: 647-407-2515

Lisa Wilson
E: [email protected]
T: 917-543-9932

Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. 
  
This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.  



These press releases may also interest you

at 00:01
The Centers for Disease Control and Prevention today releases provisional data on suicide deaths for the year 2021. According to the new data, suicide deaths in the United States increased from 45,979 to 47,646 (4%) between the years 2020 and 2021....

29 sep 2022
The FDA approves AMX0035, the first new treatment for ALS in years. The new treatment was funded by donations from the Ice Bucket Challenge, the 2014 social media phenomenon that swept the globe, with 17 million participants raising $115 million for...

29 sep 2022
Coco Life Foundation (Cocolife.black), launched in 2019, is a 501(c)(3) organization based in Philadelphia, PA. Its goal is to eliminate racial disparities in care and improve maternal health outcomes for Black mothers nationwide. Essential services...

29 sep 2022
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of sodium phenylbutyrate/taurursodiol (Relyvrio) for the treatment of amyotrophic lateral sclerosis (ALS), on September 29. Relyvrio will be made...

29 sep 2022
Vitality Products Inc. (the "Company" or "Vitality") is pleased to report its financial results for the second quarter ended July 31, 2022....

29 sep 2022
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the European Medicines Agency (EMA) has accepted for regulatory review the company's marketing authorization application (MAA) for fezolinetant, an...



News published on 18 august 2022 at 15:35 and distributed by: